Routine emergency dept. HIV screenings find only small increase in newly diagnosed HIV patients

July 18, 2010, JAMA and Archives Journals

The use of routine HIV screening in a hospital emergency department, which patients had the option to decline, was associated with only a modest increase in the number of patients with newly diagnosed HIV infection, compared to physician-directed diagnostic rapid HIV testing, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

Jason S. Haukoos, M.D., of the Denver Health Medical Center, Denver, presented the findings of the study at a JAMA media briefing at the International AIDS conference in Vienna.

Infection with the human immunodeficiency virus (HIV) remains an important public health problem in the United States, with more than 1 million people estimated to be infected, and approximately 230,000 infections being undiagnosed. Additionally, approximately 56,000 people are newly infected each year, according to background information in the article. Testing for remains an important preventive strategy, and in 2006, the (CDC) published revised guidelines for performing HIV testing in health care settings, recommending widespread routine (nontargeted) opt-out (the option to decline) HIV screening in settings where the prevalence of undiagnosed infection was 0.1 percent or greater.

Emergency departments (EDs) have been an important focus for HIV prevention efforts, including testing and screening initiatives, and since 2006, efforts to integrate nontargeted HIV screening into EDs have increased, although limited research supports this practice, and it remains unknown if nontargeted opt-out HIV screening, when incorporated into an ED setting, is associated with the identification of patients with HIV infection as a prevention strategy, the authors write.

Dr. Haukoos and colleagues conducted a study to determine whether nontargeted opt-out rapid HIV screening in a high-volume ED was associated with identification of more patients with newly diagnosed HIV infection than physician-directed diagnostic rapid HIV testing. The study included an urban hospital with an approximate annual ED census of 55,000 patient visits. Patients were 16 years or older and capable of providing consent for rapid HIV testing. The interventions included nontargeted opt-out rapid HIV screening and physician-directed diagnostic rapid HIV testing alternated in sequential 4-month time intervals between April 2007 and April 2009.

Of the 28,043 eligible patients included in the opt-out phase, 6,933 patients (25 percent) completed HIV testing (6,702 patients were screened; 231 patients were diagnostically tested). Of the 6,702 patients screened, 10 patients (0.15 percent) had new HIV diagnoses. Of the remaining 21,281 patients who opted out or were opted out by registration personnel, 231 (1 percent) subsequently underwent diagnostic testing and 5 patients (2.2 percent) had new diagnoses.

Of the 29,925 eligible patients included in the diagnostic phase, 243 patients (0.8 percent) underwent testing and 4 patients (1.6 percent) had new diagnoses. The overall prevalence of newly detected HIV infection during the opt-out phase (including those diagnostically tested) and during the diagnostic phase was 15 in 28,043 (0.05 percent) and 4 in 29,925 (0.01 percent), respectively.

The authors found that nontargeted opt-out screening was associated with newly identified HIV-infected patients. Most of these patients were identified late in the course of disease and met serological criteria for acquired immunodeficiency syndrome (AIDS) at the time of their diagnoses.

"Nontargeted opt-out rapid HIV screening in conjunction with diagnostic testing was associated with approximately 30 times the number of rapid HIV tests performed, yet only a few more patients were newly identified with infection when compared with diagnostic testing alone," the authors write.

More information: JAMA. 2010;304[3]:284-292.

Related Stories

Recommended for you

HIV exports viral protein in cellular packages

February 15, 2018
HIV may be able to affect cells it can't directly infect by packaging a key protein within the host's cellular mail and sending it out into the body, according to a new study out of a University of North Carolina Lineberger ...

Can gene therapy be harnessed to fight the AIDS virus?

February 13, 2018
For more than a decade, the strongest AIDS drugs could not fully control Matt Chappell's HIV infection. Now his body controls it by itself, and researchers are trying to perfect the gene editing that made this possible.

Big data methods applied to the fitness landscape of the HIV envelope protein

February 7, 2018
Despite significant advances in medicine, there is still no effective vaccine for the human immunodeficiency virus (HIV), although recent hope has emerged through the discovery of antibodies capable of neutralizing diverse ...

Scientists report big improvements in HIV vaccine production

February 5, 2018
Research on HIV over the past decade has led to many promising ideas for vaccines to prevent infection by the AIDS virus, but very few candidate vaccines have been tested in clinical trials. One reason for this is the technical ...

Microbiome research refines HIV risk for women

January 25, 2018
Drawing from data collected for years by AIDS researchers in six African nations, scientists have pinpointed seven bacterial species whose presence in high concentrations may significantly increase the risk of HIV infection ...

Researchers find latent HIV reservoirs inherently resistant to elimination by CD8+ T-cells

January 22, 2018
The latest "kick-and-kill" research to eliminate the HIV virus uncovered a potential obstacle in finding a cure. A recent study by researchers at the George Washington University (GW) found that latent HIV reservoirs show ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.